No Data
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $28
Express News | Mediwound Ltd - Key Safety Endpoints Include Adverse Events and Wound Closure Time
Express News | Mediwound Ltd - to Initiate Phase II Study for Escharex in 2025
Express News | Mediwound Announces Phase II Head-to-Head Study Evaluating Escharex® Vs. Collagenase in Patients With Venous Leg Ulcers
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx Vs. Collagenase in Patients With Venous Leg Ulcers
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit